LL-37 5mg (CAP-18)

Researchers evaluating LL-37 for research can begin with compound identity, certificate of analysis review, analytical testing, and lot traceability. Scientific databases describe LL-37 as a cathelicidin antimicrobial peptide associated with the human CAMP gene and the hCAP-18/CAP-18 precursor system [1] [2]. The material is supplied for laboratory research use only.

• LL-37 is a 37-residue peptide associated with the human cathelicidin antimicrobial peptide system, with CAMP, CAP18, FALL39, and LL37 appearing as related gene or synonym references in official databases [1], [2], [4].
• Published literature frames LL-37 as an antimicrobial peptide and host-defense research subject, with antimicrobial activity, membrane interaction, epithelial-cell context, and chemotactic signaling studied in model systems [5], [9], [11], [17].
• Literature can explain research context, but it should not be converted into product effects, clinical outcomes, or consumer-facing claims.
• COA review should look for identity, purity, method notes, lot number, COA date, and whether HPLC, LC-MS, or mass spectrometry data support the documentation [23], [24], [26].
• Lot traceability matters because research procurement teams need the listed peptide, COA, and batch file to point to the same research material.

Fast Answer: What Should Researchers Check Before They Buy LL-37 for Research?

Researchers evaluating where to buy LL-37 for research should first review RUO labeling, the batch-specific certificate of analysis, peptide identity data, purity testing, lot traceability, and supplier documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption.

What Documentation Should Come First?

The first document to review is the batch-specific certificate of analysis. A useful COA should identify the peptide, lot number, test date, reported purity, and analytical method.

For peptide materials, HPLC is commonly used to separate and evaluate peptide mixtures, while mass spectrometry is widely used in peptide and protein analysis because it can support mass-based identity review [26], [27]. Those methods do different jobs, so a strong documentation file should explain how each method supports the research material record.

Why Does RUO Labeling Matter Before Procurement?

RUO labeling identifies material intended for laboratory research, not clinical use or consumer applications. Study findings do not establish effects for the supplied material.

For LL-37, this is especially important because the literature spans antimicrobial peptide research, receptor models, epithelial-cell studies, and broader innate immune system context [18], [19], [21].

Research-Use-Only Scope for LL-37

LL-37 Identity References

Official references connect LL-37 to the CAMP gene, cathelicidin antimicrobial peptide entries, and curated ligand records [1] [2] [5].

What Is LL-37 in Research Literature?

LL-37 is described as a human cathelicidin antimicrobial peptide associated with the CAMP gene and hCAP-18/CAP-18 precursor terminology [1], [2]. RCSB PDB entry 2K6O lists a human LL-37 structure with 37 modeled and deposited residues and classifies the structure as an antimicrobial protein [4].

In research literature, LL-37 appears in antimicrobial peptide studies, membrane-interaction studies, chemotaxis models, epithelial-cell expression studies, and broader cathelicidin reviews [9], [10], [11], [18].

Compound Identity as a Human Cathelicidin-Derived Peptide

The CAMP gene encodes cathelicidin antimicrobial peptide, and related official database records connect the target to CAP18, FALL39, and LL37 synonyms [1], [2]. PubChem lists LL-37 under CID 16198951 with molecular formula and molecular weight data, which can support identity cross-checking during documentation review [3].

For procurement teams, the point is not to memorize every synonym. The point is to confirm that the product listing, COA, and analytical records refer to the same canonical LL-37 peptide.

CAP-18 Context for LL-37 Classification

The CAP-18/hCAP-18 context matters because LL-37 is discussed in the literature as a C-terminal peptide related to the cathelicidin precursor system. Work on FALL39 and granulocyte processing helped establish the relationship between precursor terminology and LL-37 naming in the research record [7], [8].

This is why a COA should avoid vague naming. The document should make it clear whether the tested material is LL-37 peptide, a precursor-related protein, a derivative, or another cathelicidin-family material.

Why Do Sequence and C-Terminal Details Matter?

Sequence and C-terminal details matter because peptide identity depends on the actual amino acid chain, terminal state, and analytical match. RCSB’s LL-37 structure record reports a 37-residue human cathelicidin antimicrobial peptide entity and links the structure to UniProt P49913 [4].

Small changes in sequence or terminal chemistry can change the identity of a peptide material. That is why researchers should compare the product listing, COA, molecular weight, and analytical report rather than relying on the name alone.

LL-37 as an Antimicrobial Peptide Research Material

LL-37 is widely discussed as an antimicrobial peptide in cathelicidin-family literature [9], [18], [20]. The term antimicrobial peptide describes a research class, not a product claim.

The research category identifies literature on peptide identity, membrane interaction, microbial models, receptors, and assay interpretation.

What Does Antimicrobial Peptide Classification Add?

Dürr and colleagues describe LL-37 as a 37-residue amphipathic helical peptide with broad antimicrobial activity in the literature [9]. This is a research classification, not evidence of effects for a supplied RUO material.

The classification also helps procurement teams know which documentation details matter. For a peptide in this lane, purity, identity, sequence consistency, and lot traceability are central.

Antimicrobial Activity in Assay Context

Published literature has evaluated LL-37 antimicrobial activity in model systems, including studies against Gram-negative and Gram-positive organisms [13], [18]. Sancho-Vaello and colleagues investigated LL-37 interactions with bacterial cell wall components and membrane-mimic systems, reporting structural observations relevant to membrane-disruption models [17].

These findings describe the studied models, not established performance of the supplied product.

Where Do Gram-Positive and Gram-Negative Models Fit?

Gram-positive and Gram-negative bacteria appear in LL-37 literature because antimicrobial peptide studies often compare activity across different microbial model types [13], [18]. The outer membrane of gram-negative bacteria and peptide-membrane interactions are common research themes in this area [17].

It does not change the procurement priority: verify the peptide, lot, COA, and analytical records first.

Receptor and Chemotactic Signaling Context

LL-37 literature also includes receptor and chemotactic signaling context. The IUPHAR/BPS ligand page identifies LL-37 as a cathelicidin-family antimicrobial peptide and notes FPRL-1-mediated chemotaxis in human neutrophil models [5].

Yang and colleagues reported that LL-37 could activate formyl peptide receptor-like 1 models in chemotaxis-related experiments [11]. This is a research-model statement, not product-use guidance.

What Role Do Formyl Peptide Receptor Models Play?

Formyl peptide receptor models help explain why LL-37 is not discussed only as a membrane-active antimicrobial peptide. IUPHAR/BPS lists FPR2 as a class A G protein-coupled receptor in the formylpeptide receptor family [6].

Research literature has examined LL-37 in relation to FPRL1/FPR2-linked chemotactic signaling, calcium mobilization, and leukocyte-related model systems [11], [12].

Receptor Context and Evidence Limits

Receptor context is not a product claim. It helps explain why researchers may study LL-37 across antimicrobial, epithelial, signaling, and cell-migration models.

Innate Immune Pathway Research Around LL-37

LL-37 appears in innate immune system literature because cathelicidins are host-defense peptides studied at the interface of microbial challenge, epithelial barriers, leukocyte biology, and signaling models [18], [20], [21].

How Does Cathelicidin Literature Connect With Epithelial Cells?

Epithelial-cell literature is relevant because studies have reported LL-37/hCAP-18 expression in differentiated human colon epithelium and in airway epithelial contexts [14], [15]. Keratinocyte and epithelial-cell models also appear in LL-37 expression research [16].

What Can Cell Signaling Models Show?

Cell signaling models can show how LL-37 is studied in pathway-specific experiments. For example, literature has evaluated LL-37 interactions with Toll-like receptor-related signaling contexts and nucleic-acid or ligand-associated model systems [22].

These models can help researchers understand study design. They cannot replace lot-level COA review or analytical identity verification.

Evidence Limits in Inflammation Research

Inflammation-related findings depend on the experimental model and do not establish clinical effects or suitability for consumer use.

Published Literature Interpretation for LL-37 Research

Published literature can explain what researchers have investigated. It cannot establish what an RUO product is for.

LL-37 literature includes antimicrobial peptide reviews, structural studies, epithelial-cell expression papers, receptor work, and broader cathelicidin-family summaries [9], [17], [18], [19], [20].

What Can Published Literature Support for LL-37 Research?

Published literature can support a research overview of LL-37 classification, CAP-18 context, antimicrobial peptide studies, receptor models, and analytical identity considerations. Official databases can support identity terms, gene symbols, molecular formula, and structure records [1], [2], [3], [4].

The literature can also help readers understand why LL-37 is studied in relation to cathelicidin antimicrobial peptide, epithelial cells, chemotaxis, Gram-positive and Gram-negative models, and signaling pathways [5], [11], [14], [18].

Why Should Study Findings Stay Separate From Product Claims?

Findings about receptor activity, antimicrobial activity, or wound healing require interpretation within the studied model; they do not establish outcomes for a supplied research material.

Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

Evidence Quality Framework for Research Buyers

A research buyer should evaluate evidence in layers: official database identity, peer-reviewed literature, analytical method documentation, COA consistency, and supplier transparency. No single layer replaces the others.

Source Quality Filters for LL-37 Literature Review

Start with official databases for identity. UniProt, NCBI Gene, PubChem, RCSB PDB, and IUPHAR/BPS provide curated reference points for compound naming, gene symbols, molecular data, structure, and ligand context [1], [2], [3], [4], [5].

Then use peer-reviewed literature for mechanism and model context.

Study Scope and Literature Limitations

Study scope matters. A paper may describe a specific in vitro assay, a cell model, a microbial model, or a structural system, and each model has limits.

Interpret each finding within the methods and limits of its original study. Academic findings do not establish equivalent effects for a supplied research material.

Certificate of Analysis Review for LL-37 Peptide

The certificate of analysis is the core procurement document for an LL-37 peptide listing. It should help researchers connect the product name, lot number, purity result, testing method, and analytical identity support.

A COA is not a substitute for reading the literature. It is the batch-specific file that connects a research material to its documented quality attributes.

What Should a Certificate of Analysis Show?

A certificate of analysis should show the compound name, lot number, test date, reported purity, analytical method, and any identity-supporting test notes. FDA guidance on analytical procedures discusses documentation of identity, quality, purity, and related validation data in regulated analytical contexts, which is useful background for understanding method documentation expectations [24].

For RUO procurement, the practical standard is consistency. The COA, label, and listing should tell the same story.

How Do Researchers Compare Lot-Specific Documentation?

Researchers compare lot-specific documentation by checking whether the product name, lot number, purity value, COA date, and analytical method match across records. If the listing says LL-37 peptide but the COA uses unclear naming, the supplier file should clarify the relationship before procurement.

Lot-level comparison is especially important when a page uses synonyms such as LL37, CAP-18, hCAP18, human cathelicidin, or cathelicidin LL-37. Those names should not create ambiguity.

Why Do COA Dates and Method Notes Matter?

COA dates help research buyers understand when the listed batch was tested. Method notes explain whether a purity value came from HPLC, whether identity was supported by LC-MS, and whether additional data were available.

Method details matter because HPLC can support purity review through chromatographic separation, while mass spectrometry can support molecular mass and identity assessment [26], [27]. These methods are complementary, not interchangeable.

Analytical Testing Workflow for Peptide Identity and Purity

Analytical testing should connect peptide identity and purity to documented methods. HPLC, LC-MS, and mass spectrometry each contribute a different layer of evidence [26], [27], [29].

A documentation-focused lab-test verification workflow can look like this:

1. Verify that the compound name, lot number, and label match across records.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and testing source.
7. Record storage and handling requirements in the laboratory file.

How Does HPLC Support Peptide Purity Review?

HPLC supports peptide purity review by separating components in a mixture so a chromatogram can be used to evaluate peak distribution and relative purity. Mant and Hodges describe HPLC modes used for peptide analysis and purification, including reversed-phase and other separation approaches [26].

For procurement review, the question is simple: does the COA identify the HPLC method clearly enough to support the reported purity value?

How Does LC-MS Support LL-37 Identity Review?

LC-MS combines liquid chromatography with mass spectrometry, allowing analytical workflows to connect chromatographic separation with mass-based evidence. LC-HRMS literature describes peptide-related identification and impurity characterization workflows where mass data support structural review [29].

For LL-37, LC-MS evidence should be tied to the batch file. A generic claim that a peptide is “tested” is weaker than a lot-specific record that names the method and links it to the material.

What Does Mass Spectrometry Add to Sequence Confidence?

Mass spectrometry adds molecular-mass and fragmentation-based evidence that can support peptide identity review. Reviews describe mass spectrometry as a versatile tool for peptide and protein analysis, while peptide mapping literature shows how LC-MS/MS can contribute to sequence-related confirmation in characterization workflows [27], [28].

Mass spectrometry can support identity review when paired with batch-specific documentation.

Lot Traceability and Batch Documentation Review

Lot traceability connects the product listing to the actual batch being evaluated. Without lot-level records, researchers have less context for purity, identity, COA date, and storage documentation.

In peptide procurement, the lot file should be easy to connect to the label. That is especially important when a product page uses several scientific synonyms.

Why Do Lot Numbers Matter for Research Procurement?

Lot numbers matter because they anchor analytical records to a specific batch. A purity value has little procurement value if the record cannot be tied to the material being evaluated.

Lot numbers also support repeatability. When research teams compare suppliers or reorder materials, batch-level records help them track which documentation belongs to which research material.

How Do Batch Records Support Repeatable Sourcing?

Batch records support repeatable sourcing by preserving the identity, test method, purity result, COA date, and storage file for a specific material. They also help technical teams compare documentation quality over time.

This is not only an administrative detail. In research workflows, documentation consistency supports internal review, purchasing controls, and study reproducibility.

Supplier Documentation for LL-37 Research Procurement

Supplier documentation should make it easy to evaluate LL-37 as a research peptide without leaning on marketing claims. A strong supplier file should include RUO labeling, compound identity, COA availability, purity method, identity testing, lot traceability, and storage documentation.

For research buyers, the question is not which page sounds most persuasive. The question is which listing provides transparent, reviewable records.

What Should Research Buyers Compare Across Suppliers?

Research buyers should compare COA availability, lot matching, analytical method disclosure, label consistency, storage documentation, and whether the page avoids product-claim language. Analytical-method guidance from FDA and ICH Q2(R2) emphasizes the importance of demonstrating that analytical procedures are suitable for their intended analytical purpose [25].

In the RUO setting, that principle translates into a practical review standard. The method should fit the documentation claim being made.

How Should Labels Align With COA Documentation?

Labels should align with COA documentation on compound name, lot number, catalog identity, and storage notes. If the label says LL-37 peptide and the COA uses a different synonym, the supplier file should make the relationship clear.

Researchers should also check whether the label states research-use-only positioning.

Where Does Storage Documentation Fit?

Storage documentation fits into the research record because peptide materials can be sensitive to environmental conditions, sequence-dependent stability, and handling history. Literature on peptide standards for mass spectrometry emphasizes the need for consistent generation, quantification, storage, and handling practices in analytical workflows [30].

Common Misunderstandings in LL-37 Research

Scientific terms require their research context. LL-37 literature covers several model types, each with different methods and limitations.

Common misunderstandings include:

• Published literature does not establish effects for a supplied research material.
• A purity percentage does not fully establish peptide identity.
• A COA should be batch-specific, not generic.
• Pathway relevance does not create a product claim.

Why Does Antimicrobial Protein Language Need Context?

Antimicrobial protein language needs context because LL-37 can be described through several related terms: antimicrobial peptide, cathelicidin antimicrobial peptide, human cationic antimicrobial protein, hCAP18, CAP-18, and CAMP [1], [2], [5]. These terms are not always interchangeable in a procurement file.

Synonyms can help with literature context, but the COA and label should make identity clear.

Why Pathway Findings Do Not Establish Product Performance

Receptor signaling, antimicrobial activity, and epithelial-cell findings describe specific experimental systems. Their relevance to a supplied material cannot be assumed without appropriate evidence.

Procurement Review Before Selecting LL-37 Research Materials

Procurement review should bring all evidence together: identity, COA, analytical testing, lot traceability, supplier documentation, storage records, and RUO labeling. This is the final check before a research buyer evaluates a supplier listing.

Documentation Checklist Before Buying LL-37 for Research

• Verify that LL-37 is labeled for research-use-only purposes.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by a named analytical method.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, molecular formula, molecular weight, and synonym references across records when available [1], [2], [3].
• Assess whether product-page language avoids consumer-facing, clinical, or product-performance claims.
• Document storage and handling information in the laboratory record.
• Retain the COA, label, supplier file, and analytical notes for internal review.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

How Does Review Support the Next Research Decision?

A documentation-first review supports the next research decision by reducing ambiguity. If the LL-37 product listing, COA, label, batch number, and analytical testing records align, the procurement team has a stronger basis for evaluating the material.

For research teams comparing peptide suppliers, prioritize COA availability, transparent RUO labeling, analytical method disclosure, and lot-level documentation before selecting any research-use-only peptide.

FAQs

What should researchers consider before they buy LL-37 for research?

Researchers should consider documentation quality before they buy LL-37 for research. A research-focused review should include RUO labeling, a batch-specific COA, peptide identity records, purity data, lot traceability, and supplier documentation. The goal is to evaluate the material as a laboratory research peptide, not as a consumer product or outcome-focused compound.

What does research-use-only mean for LL-37?

Research-use-only means LL-37 is intended solely for laboratory research, not consumer use. Procurement review includes the COA, lot number, identity information, and label consistency.

Why do researchers review a peptide COA for LL-37?

Researchers review a peptide COA for LL-37 because it helps connect the listed compound to batch-specific documentation. A strong COA should identify the compound name, lot number, test date, reported purity, and analytical method. It should also align with the product label and supplier documentation so research teams can evaluate consistency before procurement.

How do HPLC and LC-MS support LL-37 documentation review?

HPLC and LC-MS support LL-37 documentation review by addressing different parts of analytical testing. HPLC can support peptide purity review through chromatographic separation, while LC-MS can support peptide identity review through mass-based analytical data [26], [27]. Research teams should look for method notes that connect those records to the same batch.

What role can LPS or toll-like receptor 4 context play in LL-37 literature?

LPS and toll-like receptor 4 appear in LL-37 literature in receptor and pathway models. Bacterial lipopolysaccharides, pathogen models, and cell membrane interactions describe research context; these findings do not establish product effects or suitability for consumer use.

How should published literature be interpreted for LL-37 research materials?

Published literature should be interpreted as research context for LL-37 materials. Studies may discuss in vitro models, preclinical literature, cell proliferation, microbial systems, or organisms such as Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. Those references help frame scientific background, but procurement decisions should still focus on COA review, analytical testing, and lot traceability.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

De Yang

Author profile: PubMed author search for “Yang D”

De Yang has contributed research on human cathelicidin LL-37, including interactions with formyl peptide receptor-like 1 (FPRL1) in in vitro settings. These peer-reviewed studies investigate receptor interactions and chemotactic activities of LL-37 in leukocyte and innate immunity models.

Selected publications:

• LL‑37, the neutrophil granule– and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor‑like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells — The Journal of Experimental Medicine , 2000. DOI: 10.1084/jem.192.7.1069.
• Participation of mammalian defensins and cathelicidins in anti‑microbial immunity: receptors and activities of human defensins and cathelicidin (LL‑37) — Journal of Leukocyte Biology , 2001.

Ziv Oren

Author profile: Bohrium profile for Z Oren

Ziv Oren has authored influential studies on the structural and mechanistic properties of linear amphipathic α‑helical antimicrobial peptides, including LL‑37 and related sequences. Their research explores peptide–membrane interactions, amphipathic structural organization, and the molecular basis of antimicrobial activity, contributing important mechanistic context to the academic literature on antimicrobial peptides and peptide structure–function analysis within laboratory research paradigms.

Selected publications:

• Structure and organization of the human antimicrobial peptide LL‑37 in phospholipid membranes: relevance to the molecular basis for its non‑cell‑selective activity — Biochemical Journal , 1999.
• Mode of action of linear amphipathic α‑helical antimicrobial peptides — Biopolymers , 1998.

REFERENCES

1. UniProt Consortium. CAMP – Cathelicidin antimicrobial peptide, UniProtKB P49913. UniProt. Accessed 2026.
2. National Center for Biotechnology Information. CAMP cathelicidin antimicrobial peptide, Gene ID 820. NCBI Gene. Accessed 2026.
3. National Center for Biotechnology Information. LL-37, PubChem Compound CID 16198951. PubChem. Accessed 2026.
4. RCSB Protein Data Bank. Human LL-37 Structure, PDB 2K6O. RCSB PDB. Released 2008; updated record accessed 2026. DOI: 10.2210/pdb2K6O/pdb.
5. IUPHAR/BPS Guide to Pharmacology. LL-37 ligand page. Guide to Pharmacology. Accessed 2026.
6. IUPHAR/BPS Guide to Pharmacology. FPR2 target page. Guide to Pharmacology. Updated 2026.
7. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to LL-37 in granulocytes. European Journal of Biochemistry. 1996. PMID: 8681941. DOI: 10.1111/j.1432-1033.1996.0325z.x.
8. Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin hCAP-18 processing to LL-37 by proteinase 3. Blood. 2001. PMID: 11389039.
9. Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta – Biomembranes. 2006. PMID: 16716248.
10. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes. Biochemical Journal. 1999.
11. Yang D, Chen Q, Schmidt AP, et al. LL-37 and formyl peptide receptor-like 1 chemotaxis research. Journal of Experimental Medicine. 2000. PMID: 11015447.
12. Tjabringa GS, Ninaber DK, Drijfhout JW, et al. LL-37 chemotactic activity in neutrophil and eosinophil models. International archives of allergy and immunology. 2006. PMID: 16557028.
13. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrobial Agents and Chemotherapy. 1998. PMID: 9736536.
14. Bals R, Wang X, Zasloff M, Wilson JM. LL-37/hCAP-18 expression in human lung epithelial research. Proceedings of the National Academy of Sciences. 1998. PMID: 9689116.
15. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cathelicidin LL-37/hCAP18 expression by human colon epithelium. Infection and Immunity. 2002. PMID: 11796631.
16. Kim JE, Kim BJ, Jeong MS, et al. Expression and modulation of LL-37 in keratinocyte research models. Journal of Korean Medical Science. 2005. PMID: 16100459.
17. Sancho-Vaello E, Gil-Carton D, François P, et al. LL-37 structure in membrane-mimic research models. Scientific Reports. 2020. DOI: 10.1038/s41598-020-74401-5.
18. Ridyard KE, Overhage J. Human peptide LL-37 antimicrobial research overview. Antibiotics. 2021.
19. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the human cathelicidin peptide. Cellular Immunology. 2012. PMID: 23246832.
20. Kościuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. Molecular Biology Reports. 2012.
21. Kahlenberg JM, Kaplan MJ. LL-37 in inflammation-related research context. International Journal of Molecular Sciences. 2013.
22. Singh D, Vaughan R, Kao CC. LL-37 peptide enhancement of Toll-like receptor signal transduction in model systems. Antiviral Research. 2014.
23. United States Pharmacopeia. General Chapter <621> Chromatography harmonization information. USP. Accessed 2026.
24. U.S. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. FDA Guidance. 2015; page accessed 2026.
25. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance. 2024.
26. Mant CT, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. PMID: 18604941.
27. Zhang G, et al. Overview of peptide and protein analysis by mass spectrometry. Current protocols in protein science. 2010. PMID: 21104985.
28. Mouchahoir T, Schiel JE. LC-MS/MS peptide mapping workflow for sequence characterization. Analytical and Bioanalytical Chemistry. 2018. PMID: 29411091.
29. Zeng K, et al. LC-HRMS characterization of peptide-related identity and impurity profiles. Journal of Pharmaceutical and Biomedical Analysis. 2015.
30. Hoofnagle AN, et al. Recommendations for peptide generation, quantification, storage, and handling in mass spectrometry-based assays. Clinical Chemistry. 2016.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.